Rationale Manipulation of the stress neuropeptide corticotropin-releasing factor (CRF), specifically central antagonism of the type 1 receptors (CRF-R1), effectively reduces alcoholic-like ethanol drinking in rodents. Escalated consumption is largely controlled by neurocircuitry that is important for reward and affect, such as the ventral tegmental area (VTA) and the dorsal raphé nucleus (DRN). Objective The current studies investigated the role of CRF-R1 within the VTA and DRN and their relation to escalated ethanol drinking in two species. An additional goal was to explore whether high alcohol-drinking individuals would be more affected by CRF-R1 antagonism than low alcoholdrinking individuals. Methods With a two-bottle choice drinking procedure, adult male C57BL/6J mice and Long-Evans rats were given 24-h access to 20 % ethanol and water on an intermittent schedule. Rats and mice were implanted with cannulae targeting the VTA or DRN. Doses of the CRF-R1 antagonist CP-154,526 (butyl-[2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-yl]ethylamine)) were microinfused to modulate drinking of ethanol and water over the course of 24 h. Results In both mice and rats, intra-VTA CP-154,526 selectively decreased ethanol intake, while identical doses (0.3 and 0.6 μg) infused intra-DRN reduced both ethanol and water drinking. Long-Evans rats displayed a range of individual differences for ethanol preference, and CP-154,526 suppressed ethanol drinking in the high-preferring animals regardless of brain site manipulation. Conclusions The current findings confirm previous studies that blockade of CRF-R1 efficaciously reduces escalated drinking while also suggesting that the effects of intermittent access on alcohol consumption may require CRF interaction with dopamine in the VTA.
Introduction
The progression from social drinking to alcohol dependence can be characterized by the emergence of excessive, bingelike drinking. These episodes of binge drinking tend to occur intermittently between periods of abstinence (Sinclair and Senter 1968; Becker 1998) . Over time, a maladaptive pattern of heavy drinking and withdrawal induces neuroadaptations indicative of dependence (Koob and Le Moal 1997) . Studies in rats (Pinel and Huang 1976; Wayner and Greenberg 1972; Tomie et al. 2006; Simms et al. 2008; Cippitelli et al. 2012 ) and, more recently, mice have demonstrated that intermittent access to ethanol engenders higher voluntary and preferential ethanol consumption than continuous access to ethanol (Hwa et al. 2011a, b; Melendez 2011) .
One hypothesized mechanism for the transition to dependence is the dysregulation of brain stress systems, most notably the neuropeptide corticotropin-releasing factor (CRF) and its receptors (Koob 2003) . CRF is considered to play a key role in the anxiogenic effects of acute withdrawal, protracted abstinence, and reinstatement induced by mild footshock stress (Merlo-Pich et al. 1995; Valdez et al. 2002; Finn et al. 2007; . Most pharmacological and genetic evidence suggests that CRF exerts its effects on ethanol consumption through the activation of CRF type 1 receptors (CRF-R1) (Chu et al. 2007; Treutlein et al. 2006; Hansson et al. 2006) , with opposing action on CRF-R2 Sharpe and Phillips 2009) . CRF-R1 antagonists have been identified as potential candidates for therapeutic agents in the treatment of alcohol use disorders (Lowery and Thiele 2010) since these compounds reduce ethanol drinking in dependent animals, but not in non-dependent animals (Sabino et al. 2006; Richardson et al. 2008) . Recently, systemic application of the CRF-R1 antagonist antalarmin was shown to decrease ethanol drinking in Wistar rats (Cippitelli et al. 2012) . The current experiments investigate the effect of a prototypic CRF-R1 antagonist, microinjected into extrahypothalamic brain sites, on escalated alcohol consumption that resulted from intermittent access.
CRF-R1 antagonists may modulate the monoamine pathways that are essential for the self-administration of alcohol, for example, the ventral tegmental area (VTA). Components of the mesolimbic dopamine (DA) system, originating in the VTA, are implicated in both responsiveness to stress (Deutch et al. 1991; 1987; Thierry et al. 1976) and in positively reinforcing the effects of drugs of abuse, including ethanol (DiChiara and Imperato 1988; Gonzales et al. 2004; Koob et al. 1992; Wise 1996) . CRF-DA synapses (Tagliaferro and Morales 2008) have been detected and are the sites for stress-induced CRF release in the VTA (Wang et al. 2005 (Wang et al. , 2007 . CRF-R1 activation through the application of CRF transiently increases VTA DA neuronal firing (Korotkova et al. 2006; Wanat et al. 2008 ). However, CRF-R1 activation also facilitates slow D 2 and GABA B receptor-mediated inhibitory synaptic transmission. This enhancement can be reduced by repeated exposure to stress or drugs of abuse (Beckstead et al. 2009 ). This evidence led us to consider that high-drinking behavior, specifically at the level of the VTA, could be modulated by CRF-R1 antagonists. Alcohol-induced DA release within the NAcc is critically involved in the alcohol reinforcement process (DiChiara and Imperato 1988; Spanagel and Weiss 1999) . However, the finding that 6-OHDA-induced lesion of the mesolimbic tract failed to alter voluntary self-administration in rats suggests a less central role of DA in maintaining alcohol consumption (Rassnick et al. 1993) . Therefore, other neurotransmitters, such as serotonin, may also contribute to the development of intermittent ethanol drinking (LeMarquand et al. 1994) .
Escalated alcohol drinking may also be based on impulse flow in other monoamine pathways, including those originating from the dorsal raphé nucleus (DRN) which is mostly serotonergic in nature. CRF-immunoreactive fibers densely innervate the cell bodies of the DRN in a topographically organized manner (Kirby et al. 2000; Sakanaka et al. 1986; Swanson et al. 1983) , and particular serotonin (5-hydroxytryptamine, 5-HT) cells constitute the major origins for 5-HT projections to the forebrain (Molliver 1987; Jacobs and Azmitia 1992) . During acute stress, among other actions, CRF activates CRF-R1, inhibiting DRN 5-HT (Price et al. 1998; Price and Lucki 2001) . This decreased 5-HT may promote the increased impulsivity and, later on, the compulsion that results in intense drug-seeking behavior (Branchey et al. 1981; Tabakoff and Ritzmann 1975) . Therefore, alcohol drinking may inhibit DRN 5-HT neuron firing as a consequence of the activation of CRF-R1. In contrast, escalated alcohol drinking may increase VTA DA firing as a result of the activation of CRF-R1 or also inhibit firing after chronic ethanol. We hypothesize that intermittent ethanol drinking may be differentially affected by CRF-R1 antagonism in the VTA compared to that in the DRN.
An additional goal of the current study was to investigate how selectively CRF-R1 antagonism can affect individuals in two commonly used species of animals using the intermittent access procedure (Simms et al. 2008; Melendez 2011; Hwa et al. 2011a ). The present research used Long-Evans rats and C57BL/6 J (B6) mice to examine inherent differences in voluntary, intermittent drinking separated by brief periods of deprivation. Outbred rats may demonstrate a range of ethanol preferences in the intermittent access procedure including ethanol taste aversion (Keifer et al. 1994; Berman and Cannon 1974) , while inbred B6 mice do not exhibit this taste aversion (McClearn and Rodgers 1959) . Another reason for species differences in intake may arise from functional differences in neuroanatomy. B6 mice show less of a DA excitatory response in VTA neurons caused by ethanol in vitro (Brodie and Appel 2000) , and they show fewer DAergic fibers innervating the prefrontal cortex (D'Este et al. 2007 ) compared to lower preferring animals. These neuroanatomical differences may suggest that B6 mice may drink more ethanol and be more impulsive than Long-Evans rats. By using two animal models that display different preferences for 20 % ethanol, we intended to study how CRF acts in low-drinking vs. dependent-like drinking individuals while being subjected to an intermittent schedule of access. We hypothesized that blockade of CRF-R1 will lead to greater suppression of ethanol drinking in those who drink in excess than in those who do not.
Methods

Animals
Adult, male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) and Long-Evans rats (Charles River, Wilmington, MA), 8 weeks old upon arrival, were given 1 week to habituate to vivarium conditions on a 12-h reversed light/dark cycle (lights off at 8 AM) and maintained temperature (70±5°F) and humidity (25 %). Animals were then individually housed for the duration of the study. Mice were housed in polycarbonate cages (28×17×12 cm) with pine shavings bedding and with stainless steel wire mesh lids with two openings for bottle spouts. Rat home cages were custom-made Plexiglas chambers (25×25×30 cm) lined with Cellu-Dri™ pellet bedding (Shepherd Specialty Papers, Kalamazoo, MI) with front panels that included two angled holes for drinking spouts. Food and water were available ad libitum. All procedures were approved by the Tufts University Institutional Animal Care and Use Committee and were in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Study design B6 mice and Long-Evans rats were given intermittent access to 20 % ethanol and water for at least 4 weeks. Rats were then divided into high-ethanol-preferring individuals vs. low-ethanol-preferring individuals based on their baseline ethanol preference. High-preferring rats showed >30 % ethanol preference during both the 2-and 24-h access periods. Subjects were randomly divided into groups for cannula implants targeting either the VTA or the DRN. In a within-subjects design, animals underwent three microinjection tests (vehicle aCSF, 0.3 μg and 0.6 μg CP-154,526) on three ethanol drinking test days at least 48 h apart, consistent with the intermittent access protocol for mice of Hwa et al. (2011a) and the protocol for rats of Simms et al. (2008) . Ethanol intake in grams of ethanol per kilogram of body weight, volume of ethanol and water consumption (in milliliters), and ethanol preference (in percent) were measured 2 and 24 h after microinfusion. After microinjection testing, blood ethanol concentrations were measured on a final drinking day after a 1-h access to alcohol and water after vehicle microinjection using an ethanol assay kit (Diagnostic Chemical Limited, Oxford, CT). Cardiac blood was collected from rats and submandibular blood was collected from mice. The study design is illustrated in Fig. 1 .
Ethanol drinking
Mice and rats were given intermittent access to a two-bottle choice of 20 % ethanol and water on Mondays, Wednesdays, and Fridays for 24 h (Simms et al. 2008; Hwa et al. 2011a) . Between these ethanol and water sessions, animals were given two bottles of water in the home cage. In an additional group of B6 mice, continuous access was provided. Mice were given a two-bottle choice of 20 % ethanol and water for 7 days per week. Animals were weighed before every ethanol drinking session. Fluid access began 3 h into the dark cycle as peak fluid consumption in outbred mice (Goldstein and Kakihana 1977) and one-bottle 20 % ethanol consumption in B6 mice occur at this time of day (Rhodes et al. 2005) . To assess fluid consumption, differences in bottle weights were measured before and after the two-bottle choice to ethanol and water. On microinjection test days, 2-h fluid intake was measured in addition to 24-h intake. Although animals were given 24 h total access, it was informative to monitor acute drinking during the first hours of the two-bottle choice after the previous day's 24-h alcohol deprivation. Also, 2-h measurements allowed for drug comparisons influenced by shorter-acting microinjections.
Ethanol solutions (w/v) were prepared in tap water from 95 % ethyl alcohol (Pharmaco-AAPER, Brookfield, CT). For mice, fluids were presented in 50-ml plastic centrifuge tubes (Nalgene) with no. 5 rubber stoppers and were securely held through the wire mesh cage lid. Fluids were presented to rats in 100-ml graduated plastic cylinders with no. 6 rubber stoppers (Fisher Scientific, Agawam, MA) containing stainless steel ball-bearing sippers. To control for extraneous spillage due to experimenter handling or evaporation, weekly "drip" averages (loss of fluid in a cage with no animal present) were subtracted from individual fluid intakes.
Stereotaxic surgery
Animals underwent stereotaxic surgery for permanent indwelling cannulae in either the VTA or DRN. Mice received ketamine (100 mg/kg) and xylazine (10 mg/kg) combination and Rimadyl® (5 mg/kg) as anesthetic (10 ml/kg, i.p.) and analgesic (10 ml/kg, s.c.), respectively, preceding surgical procedures in a stereotaxic frame (Kopf Instruments, Tujunga, CA). Rats received ketamine (100 mg/kg) and xylazine (6 mg/kg) combination and Rimadyl® (5 mg/kg) as anesthetic (1 ml/kg, i.p.) and analgesic (1 ml/kg, s.c.), respectively, preceding surgery. Mice were implanted with a dual-cannulae system to bilaterally target the mouse VTA (Plastics One, Roanoke, VA) with no angle from the bregma (AP, −3.2; ML, ±0.5; DV, −4.5 mm). Dummy cannulae and dust caps fit the length of the cannula, while VTA dual injectors protruded 0.1 mm past the cannula. Other groups of mice were implanted with unilateral 6-mm, 26-gauge guide cannulae aimed at the DRN (AP, -4.2; ML, +0.5; DV, −1.9 mm from bregma) at a 26°angle (Paxinos and Franklin 2003) . Fitted obdurators protruded 0.5 mm beyond the guide cannula, while injectors protruded 1 mm beyond the guide cannula. Rats were bilaterally implanted with 11-mm, 26-gauge guide cannulae targeting the VTA (AP, −5.2; ML, +1.8; DV, −7.5 mm from the bregma) at a 10°angle or unilaterally targeting the DRN (AP, −7.5; ML, +3.2; DV, −5.8 mm from the bregma) at a 28°angle (Paxinos and Watson 1997) . Dental cement (Jet Acrylic, Lang Dental, Wheeling, IL) and two 0.5-mm tapered screws (Small Parts, Lexington, KY) anchored the cannulae permanently to the skull surface. Obdurators fit 0.5 mm beyond the guide cannulae immediately after surgery. Animals recovered 3-7 days before resuming intermittent access to 20 % ethanol drinking. Mice and rats were given at least 3 two-bottle choice sessions to return to pre-surgical drinking levels, which was defined as a <15 % variability in individual drinking across three sessions. Obdurators were handled before fluid presentation in these sessions to habituate animals to testing conditions.
Microinjection procedures
Injectors were connected via flared polyethylene tubing to a glass syringe controlled by an automatic CMA/100 microinjection pump (CMA Microdialysis, Sweden). For mice, a 33-gauge injector microinfused a 0.2-μl volume of aCSF, 0.3 or 0.6 μg, at a flow rate of 0.1 μl/min into the target brain sites. For rats, a 33-gauge, 12-mm injector(s) infused a 0.5-μl volume of aCSF, 0.3 or 0.6 μg CP-154,526, at a 0.1667-μl/min flow rate into the target brain sites. Animals moved about freely during the infusion process. Injectors remained in place for 1 min to allow for diffusion and to minimize vertical action up the cannula. Nine minutes later (a total of 10 min after drug administration), alcohol and water bottles were given to animals to assess CRF-R1 effects on fluid consumption.
Histology
After testing, mice and rats were deeply anesthetized with an i.p. injection of ketamine/xylazine combination (100 mg/kg ketamine and 10 mg/kg xylazine) or sodium pentobarbital (100 mg/kg), respectively. Animals were intracardiacally perfused with 0.9 % saline and 4 % paraformaldehyde, followed by brain removal. Brains were sliced in 55-μm coronal sections using a Cryostat (Leica CM1900, Bannockburn, IL). Nissl-stained sections were used to check placement of the guide cannulae. Animals with incorrect placements into the target sites (VTA required two correct placements; DRN required one correct placement) were excluded from the analysis (n02 mice, n09 rats). 4, pyrimidin-4-yl]ethylamine)) (Tocris, Ellisville, MO) was freshly suspended immediately before microinjections in a vehicle of aCSF. aCSF was composed of 147 mM NaCl 2 , 0.9 mM MgCl 2 , and 4.0 mM KCl and filtered through a 25-mm syringe filter before use. CP-154,526 displays high affinity for CRF-R1 (K i <10 nM) and high selectivity for CRF-R1 (>10,000 for CRF-R2) and blocks CRF-stimulated adenylate cyclase activity in rodent pituitary and cortical membranes (Lundkvist et al. 1996; Schulz et al. 1996) . Drug doses were based on previous microinjection studies in our laboratory using CP-154,526 suspended in aCSF (Boyson et al. 2011; Quadros et al., in preparation) .
Drugs
Statistical analyses
Statistical analyses were performed using SigmaStat version 3.1 (Systat Software, San Jose, CA). The mean and standard Fig. 1 Study design to test intracerebral CRF-R1 antagonist manipulation of ethanol-drinking animals. C57BL/6J mice were given intermittent (IAA) or continuous (CAA) 24-h access to 20 % ethanol and water. Long-Evans rats were also given intermittent access to alcohol (IAA) then characterized into high-ethanol-preferring rats (High EtOH Pref) or low-ethanol-preferring rats (Low EtOH Pref). After cannulation targeting either the ventral tegmental area (VTA) or the dorsal raphé nucleus (DRN), multiple doses of CP-154,526 were microinfused to suppress alcohol drinking behavior after 2 or 24 h of fluid access. Blood ethanol concentrations (BEC) were taken after drug testing, and histological analysis confirmed cannula placement at the end of experiments error about the mean (SEM) are reported for all resulting data. Two-hour and 24-h ethanol consumption (in grams per kilogram), volume of ethanol intake (in milliliters), and water intake (in milliliters) after microinjection of CP-154,526 doses were analyzed using one-way analysis of variance with repeated measures, followed by Bonferroni post hoc analyses if significant main effects were found (p<0.05). Pearson's correlation coefficient was calculated to compare baseline ethanol drinking behavior to the change of intake as a result of CP-154,526. Ethanol preference ratios were also calculated for baseline ethanol drinking, defined as the volume of ethanol consumed (in milliliters) divided by the volume of total fluid consumed (in milliliters) multiplied by 100 (in percent). The results for the two brain sites were analyzed separately. Since the rats generally demonstrated preference for water, ethanol drinking was analyzed separately from water drinking in all tests. Data for the two species were also analyzed separately because of the large differences in baseline ethanol preference between LongEvans rats and B6 mice.
Results
Baseline ethanol drinking
C57BL/6J mice
Male B6 mice (n024) were given intermittent 24-h access (IAA) to 20 % ethanol and water for 4 weeks or 12 twobottle choice sessions. IAA mice acquired high ethanol drinking levels rapidly over the first week and maintained escalated ethanol consumption at 22.46±1.69 g/kg per 24 h (Fig. 2a) and ethanol preference at 63.15±4.82 % (Fig. 2b) .
IAA mice also showed robust ethanol drinking levels during the initial 2 h at 4.49±0.34 g/kg (Fig. 2a) and ethanol preference at 59.41±6.56 % (Fig. 2b) . After vehicle microinjection, IAA mice achieved average blood ethanol concentrations of 145.34±27.20 mg/dl after 1-h access of the two-bottle choice. Another group of mice (n024) was given continuous 24-h access (CAA) for 12 consecutive days. CAA mice also acquired high ethanol drinking during both the initial 2-h access period and the 24-h overnight access period (Fig. 2a) , but they consumed less alcohol than IAA mice. CAA mice showed less ethanol preference than IAA mice at 44.08±4.05 % overnight and even less during the initial 2-h access period at 36.24±4.60 % (Fig. 2b) . After vehicle microinjection, CAA mice showed average blood ethanol concentrations of 79.37±12.03 mg/dl after 1-h ethanol and water access.
Of the 24 IAA mice and 24 CAA mice, half received VTA implants and half received DRN implants. Two IAA and three CAA mice implanted intra-VTA did not survive the cannulation surgery. Two IAA and four CAA mice implanted intra-DRN were eliminated due to missed cannula placements or did not survive surgery. Schematics and photomicrographs of VTA and DRN placements in the mouse brain are shown in Fig. 3 .
Long-Evans rats
In rats, intermittent access resulted in ethanol consumption (in grams per kilogram) steadily increasing over time, but we observed a distribution of individual differences for ethanol intake and preference. After correlational analyses, rats were characterized as high-ethanol-preferring rats or low-ethanol-preferring rats based on their baseline ethanol drinking behavior. High-ethanol-preferring rats consumed 5.90±0.76 g/kg per 24 h (Fig. 2a) and showed a 42.23± 3.25 % ethanol preference over 24 h (Fig 2b) . High-ethanolpreferring rats also displayed an even greater 53.59±6.26 % ethanol preference during the initial binge period (Fig. 2b) . After vehicle microinjection, high-ethanol-preferring-rats had average blood ethanol concentrations of 112.28 ± 32.27 mg/dl after 1 h of the two-bottle choice. In contrast, low-ethanol-preferring rats demonstrated <1 g/kg ethanol intake during the 2-and 24-h access periods (Fig. 2a) . This group also showed lower than 25 % ethanol preference during both the 2-and 24-h access periods. Low-ethanolpreferring rats showed mean blood ethanol concentrations of 50.54±4.41 mg/dl after 1-h access. After recovery from stereotaxic surgery, animals maintained stable drinking levels. Sixteen high-ethanolpreferring rats were implanted into the VTA (n 07) or DRN (n09). Twenty-one low-ethanol-preferring rats were implanted into the VTA (n06) or DRN (n015). One rat in the VTA group and eight rats in the DRN group were eliminated due to missed cannula placements. Upon further analysis of missed DRN placements, there was a trend of cannula placements into the periaqueductal gray not having an effect on drinking behavior. We also observed a trend for decreased alcohol drinking when cannula placements were located in the cerebral aqueduct. Placements targeting the VTA or DRN in the rat brain are depicted in Fig. 4 . There were no differences in cannula placements between the high-and low-ethanol-preferring groups.
Intra-VTA modulation of ethanol drinking IAA mice IAA mice receiving intra-VTA microinfusions (n 010) showed an acute suppression of ethanol drinking (in grams per kilogram) behavior in the initial 2 h [F(2,9)017.33, p< 0.001; not shown]. Both doses significantly decreased ethanol drinking (in grams per kilogram) compared to vehicle (aCSF vs. 0.3 μg: t 04.60, p<0.001; aCSF vs. 0.6 μg: t05.48, p<0.001). CP-154,526 microinjections also Fig. 3 Histological verification of cannulae placement in C57BL/6J mice. Correct (black circles) and incorrect (white circles) cannula placements are shown in representative coronal sections (in millimeters from the bregma) surrounding the VTA or DRN (n02 excluded). VTA placements are bilateral, though only one of the two sides is shown for clarity. DRN placements are unilateral. Photomicrographs of correct placements are shown after Nissl staining reduced the volume of ethanol consumed (in milliliters) in a similar fashion [F(2,9)017.40, p<0.001; Fig. 5a ]. Ethanol intake (in milliliters) was lower after both doses compared to the vehicle treatment (aCSF vs. 0.3 μg: t04.57, p<0.001; aCSF vs. 0.6 μg: t 05.51, p<0.001). This suppression appeared to be dose-dependent, as indicated by a linear trend analysis (r 2 00.87). Two-hour water intake (in milliliters) was not affected (p00.46). Intra-VTA CP-154,526 continued to reduce ethanol intake (in grams per kilogram per 24 h) overnight [F(2,9)010.08, p<0.01; not shown], specifically at the 0.6-μg drug dose (t04.04, p<0.05). Microinjections also suppressed the volume of ethanol consumed (in milliliters) over 24 h [F(2,9)010.09, p<0.01] also at the highest dose (t03.63, p<0.01). Overnight water drinking (in milliliters per 24 h) in mice was not affected by intra-VTA microinjections of the CRF-R1 antagonist (p00.34).
CAA mice
Like the IAA mice, intra-VTA CP-154,526 microinjections reduced 2-h ethanol intake (in grams per kilogram) in CAA mice (n09) [F(2,8) Fig. 5b ] also at the 0.6-μg dose (t0 3.22, p<0.05) without significantly altering acute water consumption (in milliliters per 2 h, p00.80). Linear trend analysis confirmed an apparent dose-dependent suppression Fig. 4 Histological verification of cannulae placement in Long-Evans rats. Correct (black circles) and incorrect (white circles) cannula placements are depicted in representative coronal sections (in millimeters from the bregma) surrounding the VTA (n01 excluded) or DRN (n07 excluded) for adult male Long-Evans rats. VTA placements are bilateral, though only one of the two sides is shown for clarity. DRN placements are unilateral. Photomicrographs of correct placements are shown after Nissl staining (r 2 00.96). For 24-h ethanol drinking, intra-VTA microinjections into CAA mice did not affect ethanol consumption per body weight (in grams per kilogram, p00.71), volume of ethanol intake (in milliliters, p00.48), or volume of water intake (in milliliters, p00.48) overnight.
High-ethanol-preferring rats
High-ethanol-preferring rats (n06) also demonstrated an acute attenuation of ethanol drinking (in grams per kilogram per 2 h) [F(2,5)015.95, p<0.01] caused by both doses of intra-VTA CP-154,526 (aCSF vs. 0.3 μg: t03.38, p<0.05; aCSF vs. 0.6 μg: t 05.58, p< 0.001). CP-154,526 also decreased the volume of ethanol drinking (in milliliters) [F(2,6)021.61, p<0.001; Fig. 5c ] resulting from the differences in both drug doses (aCSF vs. 0.3 μg: t04.04, p<0.01; aCSF vs. 0.6 μg: t06.47, p<0.001) compared to no significant change in water drinking (in milliliters, p00.86) in the first 2 h of access to the two-bottle choice. Linear trend analysis confirmed the apparent dose-dependent suppression (r 2 00.87). By the 24-h time point, intra-VTA infusions of CP-154,526 did not alter ethanol consumption per body weight (in grams per kilogram, p00.86), or total volume of ethanol (in milliliters, p00.61), or water consumed (in milliliters, p00.13).
Low-ethanol-preferring rats
Intra-VTA CP-154,526 significantly reduced ethanol consumption in the initial 2-h access (in grams per kilogram) of low-ethanol-preferring rats (n06) [F(2,5) 013.59, p<0.05]. Both drug doses were significantly different from vehicle (aCSF vs. 0.3 μg: t03.78, p<0.05; aCSF vs. 0.6 μg: t05.00, p<0.01). There was also a similar suppression in volume of ethanol intake (in milliliters per 2 h) [F(2,5)013.06, p<0.01; Fig. 5d ] at both the 0.3-μg dose (t03.66, p<0.05) and the 0.6-μg dose (t04.92, p<0.01). The volume of water intake during the initial two-bottle choice period was not affected by drug treatment (p00.83). During the 24-h access period, neither ethanol consumed per units of body weight (in grams per kilogram, p00.09), ethanol volume (in milliliters, p00.08), or water volume (in milliliters, p00.49) was affected by CP-154,526 intra-VTA in low-ethanol-preferring rats.
Intra-DRN modulation of ethanol drinking
IAA mice
Like intra-VTA microinjections of IAA mice, intra-DRN microinjections of IAA mice (n08) displayed a significant Fig. 6a ]. This effect was largest at the highest dose compared to vehicle (t03.68, p<0.01). Linear trend analysis confirms this apparent dose-dependent decrease (r 2 00.92). Water drinking (in milliliters) seemed to be attenuated by CP-154,526 in the mouse DRN, but this effect was not statistically significant (p00.18; Fig. 7a ). After the 24-h two-bottle choice, mice showed no significant changes in ethanol drinking (in grams per kilogram, p00.44) or in fluid consumption (in milliliters) due to drug microinjections in the DRN (ethanol: p00.39; water: p00.70).
CAA mice
In CAA mice (n08), intra-DRN microinjections reduced ethanol drinking (in grams per kilogram), but to a lesser degree than intra-VTA CAA mice [F(2,7)05.69, p<0.05]. Only the highest drug dose was effective at reduced CAA in the DRN compared to vehicle (t03.17, p<0.05) . Similarly, CP-154,526 acutely decreased the volume of ethanol intake (in milliliters) [F(2,7)06.09, p<0.05, r 2 00.88] without altering water intake (in milliliters, p00.98; Fig. 6b ). Intra-DRN drug treatment did not alter 24-h ethanol drinking per body weight (in grams per kilogram, p00.44) or volume of ethanol intake (in milliliters, p00.37). However, the total water consumed overnight was significantly decreased after CP-154,526 in CAA animals [F(2,7) 05.26, p < 0.05], specifically at the 0.6-μg dose compared to vehicle (t02.94, p<0.05).
High-ethanol-preferring rats
In high-ethanol-preferring rats (n07), intra-DRN microinjections significantly attenuated 2-h ethanol drinking (in grams per kilogram) [F(2,6)023.41, p<0.001]. This drug effect was evident at both the moderate drug dose (t04.41, p<0.01) and the highest drug dose compared to the vehicle condition (t06.56, p<0.001). CP-154,526 also reduced the volume of ethanol (in milliliters) in the first 2 h of fluid access [F(2,6)020.36, p<0.001; Vehicle (v) aCSF, 0.3, and 0.6 μg CP-154,526 were microinjected into the dorsal raphé nucleus (DRN) of mice given intermittent access (n08) (a) or continuous access to alcohol (n08) (b). Highethanol-preferring Long-Evans rats (n07) (c) or low-ethanolpreferring rats (n09) (d) were also tested for intra-DRN modulations of fluid drinking. Mean fluid intake (in milliliters) over the initial 2-h access period is displayed (±SEM). Both 20 % ethanol (black circles) and water (white circles) intakes were measured in the two-bottle choice procedure. *p<0.05 compared to vehicle, **p<0.001 compared to vehicle aCSF vs. 0.6 μg: t06.16, p<0.001). Acute water drinking was not affected by drug treatment (p00.92). Intra-DRN infusions of CP-154,526 did not alter total 24-h ethanol drinking (in grams per kilogram, p00.59) or fluid consumption (in milliliters; ethanol: p00.91; water: p00.51) in the high-ethanol-preferring rats.
Low-ethanol-preferring rats
In contrast to the high-ethanol-preferring group, lowpreferring rats (n09) were not significantly affected by intra-DRN CP-154,526 at the 2-h time point (p00.89). The lack of the drug effect was also shown in no alterations in volume of ethanol intake (in milliliters, p00.84; Fig. 6d ). However, there was a non-significant reduction in acute water intake (p00.052; Fig. 6d ), but this trend did not last over the 24-h access period (p00.27). Similarly, intra-DRN microinjections did not affect 24-h ethanol consumption (in grams per kilogram, p00.30) or volume of ethanol intake (in milliliters, p00.31).
Change in ethanol drinking according to baseline ethanol preference
Since CRF-R1 antagonists have been reported to affect ethanol drinking in dependent rodents more than in nondependent rodents, we expected that animals which show higher baseline drinking behavior would also show greater reductions in ethanol drinking caused by CP-154,526. In both IAA and CAA mice, we observed a moderate, but significant, correlation between baseline 2-h ethanol intake (in grams per kilogram) and the absolute change in milliliters of ethanol consumed after the highest dose of CP-154,526 (r0−0.65, p<0.001; Fig. 7a ). We also observed a similar correlation across high-ethanol-preferring rats and low-ethanol-preferring rats, though the rat drinking levels were overall less than the mice in 2 h (r0−0.58, p<0.01; Fig. 7b ). Still, individuals that had a high baseline binge drinking behavior were more affected by the CRF-R1 antagonist, while individuals with a low baseline drinking behavior were less affected.
Discussion
In a cross-species comparison, this set of experiments investigated high alcohol drinking that was particularly sensitive to CRF-R1 intervention. Intermittent access to 20 % ethanol was a successful method to escalate voluntary alcohol consumption over time compared to continuous access. Outbred Long-Evans rats given intermittent access demonstrated individual differences for ethanol-drinking behavior. Some rats displayed low to moderate ethanol drinking, while some individuals consistently displayed high ethanol preference, both in the initial 2-h access period and in the overnight access period, mimicking high ethanol preference in B6 mice. Overall, CP-154,526 in the VTA reduced alcohol consumption in all animals, whereas only the highalcohol-preferring animals, the B6 mice and high-preferring rats, were responsive to CRF-R1 antagonism in the DRN. Thus, the data suggest differences between brain sites in how selective the prototypic CRF-R1 antagonist CP-154,526 can decrease high-ethanol drinking in some individuals but not others. The present investigation found that microinfusion of CRF-R1 antagonist into the VTA selectively decreased ethanol binge drinking without altering water drinking. Many classic studies have reported the impact of ethanol on the mesolimbic dopamine system (Gessa et al. 1985; Pfeffer and Samson 1986; Carlsson et al. 1974; Gatto et al. 1994) . Recent work suggests an essential role for synaptic Lower-ethanol-drinking animals (CAA mice and low-ethanolpreferring rats) are shown in white circles plasticity in the VTA in the early behavioral responses following initial drug exposures as well as in triggering long-term adaptations in regions innervated by DA neurons of the VTA (Kauer 2004; Kauer and Malenka 2007) . This set of pharmacological experiments is consistent with previous electrophysiological findings that CRF potently influences DA neurons in the VTA, which may shape an individual's likelihood for relapse (Wang et al. 2005) . In addition to altered DA neurotransmission during relapse, withdrawal from chronic ethanol leads to substantial decrements in DA firing in the VTA (Diana et al. 1992; Shen and Chiodo 1993) and extracellular NAcc DA levels Weiss et al. 1996) . Acute treatment with CRF-R1 antagonist CRA-0450 in the VTA significantly increased DA neuronal activity in the NAcc and reduced cocainestimulated DA overflow in the NAcc (Lodge and Grace 2005) . The current study supports the crucial role of the VTA in ethanol drinking since acute blockade of CRF-R1 potently reduced alcohol intake in all animals. These results are consistent with the hypothesis that long-term drug taking may decrease stress-enhanced DA transmission. We speculate that CP-154,526 acts on hyporesponsive DA neurons to increase DA flow, thereby reducing alcohol drinking behavior, which is a focus of future study. We found that CP-154,526 infusion in the rat DRN produced differential effects on high-ethanol-preferring rats compared to low-ethanol-preferring rats. High-preferring rats, in a similar fashion as high-preferring B6 mice, showed a suppression of ethanol drinking. In contrast, CP-154,526-infused intra-DRN of low-preferring rats had no effect on ethanol drinking. This interaction was only apparent at the level of the rat DRN as identical doses in the VTA significantly suppressed ethanol intake in all individuals. A change in CRF receptor signaling in the DRN may occur during the intermittent access procedure since increased drinking may result from the repeated, stress-inducing cycles of binging and withdrawal. One interpretation is that during acute stress, CRF acts on CRF-R1 subtypes, decreasing 5-HT impulse flow and release (Valentino and Commons 2005) . A limitation was that intra-DRN microinjections tended to suppress water drinking acutely or overnight in several groups of animals. CRF has been reported to decrease water intake in CRF-R1-deficient mice (Contarino et al. 2000) , which may explain the decrease in water drinking after the application of a CRF-R1 antagonist. CRF, or more likely urocortin 1, acts also on CRF-R2 since CRF-R2 is more abundant in the DRN than CRF-R1 (Chalmers et al. 1995) . CRF-R2 activation has also been associated with decreases in feeding (Spina et al. 1996; Pelleymounter et al. 2000) . We also cannot discount the role of urocortin 1 in the centrally projecting Edinger-Westphal nucleus (Giardino et al. 2011 ) that may have terminals on VTA and DRN neurons. Urocortin 1 neurons have been known to interact in the DRN to regulate fluid consumption, as well .
Furthermore, future studies need to isolate which specific CRF receptor populations within the brain are involved in the regulation of excessive drinking. Since the posterior vs. anterior VTA (pVTA and aVTA, respectively) differ in efferent DA neurons, the two subregions may be differentially involved in binge drinking (Rodd et al. 2004; Melon and Boehm 2011) . In the rats, most placements were in the pVTA, which is consistent with the past literature implicating the pVTA and alcohol seeking (Rodd et al. 2004; Hauser et al. 2011) . In the mice, as illustrated in Fig. 3 , six placements were in the aVTA. Mice with placements in the aVTA still showed reductions in drinking, though the decreases appeared to be less substantial than the reductions in drinking from mice in the pVTA. Further methodological refinements are required in order to localize microinjections in the anterior vs. posterior VTA of mice. Likewise, 5-HT receptor densities differ according to subregions of the DRN (Graeff et al. 1996; Kirby et al. 2000) . Monoaminergic impulse flow to the forebrain could vary according to subregions. Again, microdialysis studies would be useful to measure DA and 5-HT concentrations as a function of CRF-R1 blockade from different CRF receptor populations.
This cross-species comparison confirmed that blockade of CRF receptors can reduce escalated ethanol drinking in high-drinking rodents, but has less of an effect on ethanol consumption in non-dependent rodents (Chu et al. 2007; Finn et al. 2007; Gehlert et al. 2007; Valdez et al. 2002) . This implies that intermittent access to alcohol may generate withdrawalrelated binge drinking that causes changes in the CRF system in some animals. Our results are consistent with research linking CRF-R1 antagonists to reduce binge-like drinking, but not non-binge-like drinking (Lowery-Gionta et al. 2012; Sparta et al. 2008) . In line with this hypothesis, even though rats bred for high ethanol preference may be innately high consumers, these animals do not show reduced ethanol seeking due to CRF-R1 antagonism if they are not rendered dependent via exposure to alcohol vapor (Sabino et al. 2006; Gilpin et al. 2008) . B6 mice are known for their high voluntary ethanol consumption (Fuller 1964; McClearn and Rodgers 1959) and, in the current procedure, exhibited consistently escalated drinking at >20 g/kg/day (Hwa et al. 2011a ) as well as blood ethanol concentrations between 100 and 200 mg/dl. Intermittent access generated increased daily drinking in outbred rats, confirming similar values in previous studies (Cippitelli et al. 2012; Simms et al. 2008; Wise 1973) . Unlike the consistently high-alcohol-preferring mice, the Long-Evans strain of rat provided the opportunity to also study large individual differences in episodic drinking. Using intermittent access to escalate voluntary drinking, CRF may play an important role in certain extrahypothalamic sites in animals undergoing withdrawal stress. There may be a dysregulation of CRF-R1 receptors or an accumulation of CRF in these sites that increases the efficacy of the CRF-R1 blockade. Quantifying CRF-R1 mRNA or CRF levels in the brain would help clarify this hypothesis. Still, the current preparation does not adequately assess an animal's motivation for alcohol, so experiments using progressively higher behavioral demands to obtain alcohol reinforcement would be useful to further confirm the CRF-escalated drinking hypothesis.
The current study adds to the substantial preclinical evidence supporting CRF-R1 antagonists as treatment of alcohol abuse disorders, but the successful replications in various experimental preparations and species have failed to work in the clinic (recently reviewed by Zorrilla and Koob 2010) . Most notably, pharmaceutical development of nonpeptide CRF-R1 antagonists has been hindered because most compounds were either undesirably hydrophobic or difficult to deliver (Zorrilla and Koob 2004; Chen 2006) . CRF also modulates numerous neurobiological systems, including feeding, anxiety and depression, and HPA axis signaling (Hauger et al. 2006; Heinrichs and Richard 1999; Smith and Vale 2006; Menzaghi et al. 1994; Kehne 2007; Ryabinin and Weitemier 2006) . Chronic dampening of the CRF system may render unwanted side effects on vital systems outside of the specific pathways implicated in ethanol abuse, for example, peripheral or hypothalamic CRF receptors.
In conclusion, the present findings suggest that intermittent access to ethanol is based on CRF mechanisms within discrete neural circuits. Ongoing studies are further confirming the role of CRF-R1 within the DRN by testing their interaction with mu opioid receptors (Hwa et al. 2011b, meeting abstract) . Co-infusions of intra-DRN CP-154,526 and naltrexone may exert a more effective suppression of intermittent ethanol drinking via receptor disinhibition on serotonin neurons. The present results show acute drug effects that are limited to the initial 2-h access period. In nearly all treatment groups, animals compensated over the 24-h access period to return to overnight intake levels before any drug treatment. This may represent a significant limitation with microinjections as drug effects in the clinic need to be long-lasting. Current experiments hope to address this problem by implementing chronic i.c.v. dosing of CP-154,526 delivered via an osmotic minipump. Central CP-154,526 also effectively blocks intermittent access ethanol consumption for more than 72 h when administered chronically (Hwa et al. 2011b ). Again, focusing on the regulation of extrahypothalamic CRF seems crucial to understanding the vulnerability to alcohol use disorders. These pathways may play a part in determining the neurobiological differences between individuals who consume alcohol in excess and those who do not.
